Kanaph Therapeutics Inc. (KOSDAQ:0082N0)

Market Cap	492.95B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	13.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	215,554
Average Volume	271,014
Open	37,550
Previous Close	36,900
Day's Range	35,600 - 38,300
52-Week Range	32,850 - 70,000
Beta	n/a
RSI	42.29
Earnings Date	n/a

About Kanaph Therapeutics

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker ther...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 0082N0